ERBB2 and cancer: Since anti-HER2 ADCs have been reported to be effective in HER2-low expression cancers (13, 15, 17, 18), the patient was recommended the cross-indication anti-HER2 ADC, RC48 (initially at a dosage of 60 mg, followed by 120 mg every two weeks).